Clinical Trials Logo

Psoriasis clinical trials

View clinical trials related to Psoriasis.

Filter by:

NCT ID: NCT04080648 Completed - Psoriasis Vulgaris Clinical Trials

Therapeutic Drug Monitoring of Guselkumab in Psoriasis Patients

BIOLOPTIM-GUS
Start date: June 27, 2018
Phase: Phase 4
Study type: Interventional

Biologic such as guselkumab are currently the most effective treatment option for patients with moderate to severe psoriasis. But they are costly for healthcare systems and still described according to a 'one dose fits all' dosing regimen, leading to potential over- and undertreatment. In this study we aim to investigate the predictive value of early serum trough levels of guselkumab and determine the therapeutic window of guselkumab in psoriasis patients.

NCT ID: NCT04080206 Completed - Plaque Psoriasis Clinical Trials

A Safety Study of 188-0551 Spray Versus Reference Listed Drug (RLD) in Adult Subjects With Plaque Psoriasis

Start date: April 7, 2020
Phase: Phase 2
Study type: Interventional

Adrenal suppression effects of corticosteroids are among the most important safety concerns for this group of products. This study is to determine and compare the adrenal suppression potential and the pharmacokinetic (PK) properties of 188-0551 Spray versus an FDA-approved drug (also known as a "Reference Listed Drug" [RLD]) under maximal use conditions when applied twice daily (approximately every 12 hours) in adult subjects with stable, moderate to severe, plaque psoriasis.

NCT ID: NCT04074070 Completed - Psoriasis Clinical Trials

Prevalence of Sonographic Abnormalities of Joints and Entheses in Psoriasis Patients With or Without Musculoskeletal Complains

EchoPso
Start date: February 18, 2020
Phase:
Study type: Observational

The objectives of this study are: - to estimate the prevalence and severity of inflammatory (synovitis, tenosynovitis, enthesitis, dactylitis) and structural (erosions, osteophytes, enthesophytes, cortical irregularities ) ultrasound lesions in psoriasis patients with or without related musculoskeletal symptoms; - to compare them to healthy subjects or patients suffering from rheumatoid arthritis and osteoarthritis.

NCT ID: NCT04061252 Completed - Clinical trials for Palmoplantar Pustulosis

A Study of KHK4827 in Subjects With Palmoplantar Pustulosis

Start date: August 10, 2019
Phase: Phase 3
Study type: Interventional

Evaluation of efficacy and safety of KHK4827 in Subjects with Palmoplantar Pustulosis

NCT ID: NCT04057937 Completed - Clinical trials for Palmoplantaris Pustulosis

A Study to Evaluate the Efficacy and Safety of Apremilast (CC-10004) in Japanese Subjects With Palmoplantar Pustulosis

Start date: October 16, 2019
Phase: Phase 2
Study type: Interventional

This study will evaluate whether apremilast is better than placebo (inactive substance in the same form as the drug) for the treatment in Japanese subjects with PPP. This study also will evaluate the safety and tolerability of apremilast in Japanese subjects with PPP.CC-10004-PPP-001 is a multicenter, randomized, double-blind, placebo-controlled, parallel group, Phase 2 study of apremilast in Japanese subjects with PPP and inadequate response to treatment with topical steroid and/or topical vitamin D3 derivative preparations. The placebo-controlled period will be 16 weeks and patients will receive apremilast or placebo. After the 16-week placebo-controlled period, all subjects will receive apremilast for 16 weeks. All subjects will have their final study visit 4 weeks after stopping apremilast treatment.

NCT ID: NCT04053881 Completed - Plaque Psoriasis Clinical Trials

A Study to Assess How Well Certolizumab Pegol Works in Patients With Moderate to Severe Plaque Psoriasis as Part of Routine Clinical Practice

CIMREAL
Start date: August 21, 2019
Phase:
Study type: Observational

The purpose of the study is to assess the effectiveness of certolizumab pegol in patients with moderate to severe plaque psoriasis as part of routine clinical practice.

NCT ID: NCT04053387 Completed - Plaque Psoriasis Clinical Trials

Long Term Extension Study of Tapinarof for Plaque Psoriasis in Adults (3003)

Start date: August 13, 2019
Phase: Phase 3
Study type: Interventional

This is a long-term, open-label, multicenter, study to evaluate the safety and efficacy of topical tapinarof cream, 1% in adults with plaque psoriasis. Subjects in this study completed treatment in 1 of 2 Phase 3 pivotal efficacy and safety studies (Study DMVT-505-3001 or Study DMVT-505-3002). This study will consist of up to 40 weeks of treatment and a 4-week safety follow-up period.

NCT ID: NCT04042103 Completed - Plaque Psoriasis Clinical Trials

Maximal Use Study of Tapinarof Cream, 1% in Adults With Extensive Plaque Psoriasis

Start date: July 23, 2019
Phase: Phase 2
Study type: Interventional

This is an open-label, multicenter study to evaluate the systemic exposure and safety of topical tapinarof cream, 1% under conditions of maximal use in adults with plaque psoriasis.

NCT ID: NCT04031027 Completed - Plaque Psoriasis Clinical Trials

A Study to Describe the Characteristics of Patients Treated With Apremilast for Plaque Psoriasis in Italian Routine Clinical Practice

DARWIN
Start date: July 22, 2019
Phase:
Study type: Observational

The DARWIN study is an Italian multicenter, observational, cross-sectional study involving both a primary data collection (at enrollment visit) and secondary use of data (retrospective observation period). DARWIN will describe patients' characteristics in Italian routine clinical practice as well as the medication utilization patterns, including needs and benefits form the patient's perspective.

NCT ID: NCT04018599 Completed - Clinical trials for Rheumatoid Arthritis

Comparison of PK and Tolerability of MSB11022 Administered by AI or PFS

Start date: July 15, 2019
Phase: Phase 1
Study type: Interventional

The primary objective of this study is to demonstrate equivalence of the pharmacokinetic (PK) profile of MSB11022 administered by either an auto-injector (AI) or a pre-filled syringe (PFS) as single subcutaneous (s.c.) injection of 40 mg.